Stockscreener 앱 받기
15.88
2.38%
0.3621
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris CFO leaving Canonsburg pharma giant - WPXI
Are Wall Street Analysts Bullish on Viatris Stock? - Barchart
Viatris To Go Ex-Dividend On May 22nd, 2026 With 0.12 USD Dividend Per Share - Moomoo
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Gears Up to Report Q1 Earnings: What's in the Cards? - Yahoo Finance
Viatris Names Paul Campbell Interim CFO as Doretta Mistras Announces Departure - citybiz
Maryland reaches $4.5 million settlement with EpiPen makers - Baltimore Sun
Edwards names Theodora Mistras as CFO - MedTech Dive
Davis Selected Advisers (NASDAQ: VTRS) reports 78.21M shares, 6.8% stake - Stock Titan
MSN Money - MSN
Avoiding Lag: Real-Time Signals in (VTRS) Movement - Stock Traders Daily
Viatris declares $0.12 quarterly dividend per share - Investing.com
Viatris declares $0.12 quarterly dividend per share By Investing.com - Investing.com Canada
Viatris sets June 17 payment for $0.12 a share quarterly dividend - Stock Titan
Viatris Announces CFO Transition: Theodora Mistras Departs, Paul Campbell Appointed Interim CFO - Minichart
Viatris declares $0.12 quarterly dividend payable June 17, 2026. - Pluang
Viatris CFO to depart; interim CFO named - MSN
Viatris Names Paul Campbell Interim Chief Financial Officer - TipRanks
Viatris Announces Chief Financial Officer Transition - The Malaysian Reserve
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris CFO Doretta Mistras to leave, Paul Campbell named interim By Investing.com - Investing.com Australia
Edwards Lifesciences Announces Appointment of CFO - Business Wire
Viatris (Nasdaq: VTRS) appoints Paul Campbell as interim CFO - Stock Titan
Earnings Preview: Viatris to Report Financial Results Pre-market on May 07 - Moomoo
Viatris Contraceptive Patch Data Puts Women’s Health Growth Story In Focus - Sahm
Is It Too Late To Consider Viatris (VTRS) After Its Strong One Year Share Price Run - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
VTRS SEC FilingsViatris Inc Ord Shs 10-K, 10-Q, 8-K Forms - Stock Titan
Viatris presents data on low-dose contraceptive patch at ACOG By Investing.com - Investing.com India
Viatris presents data on low-dose contraceptive patch at ACOG - Investing.com
Weekly birth control patch data gets 6 slots at major OB-GYN meeting - Stock Titan
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting - ChartMill
Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30? - Insider Monkey
Vanguard discloses 7.36% stake in Viatris (NASDAQ: VTRS) - Stock Titan
Merz Gets 2 More Months To Block Generic MS Drug - Law360
Viatris (VTRS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Inc Profile: Summary - OpenSecrets
Trazodone Market Growth Size 2026, Trends, Industry Analysis, - openPR.com
Viatris Inc. (VTRS) Stock Analysis: Exploring Potential Gains With A 7.76% Upside - DirectorsTalk Interviews
Does Xanax XR Recall Over Dissolution Issues Change The Bull Case For Viatris (VTRS)? - simplywall.st
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Viatris shares break six-session winning streak - MSN
Viatris Inc. stock rises Friday, outperforms market - MSN
VTRS Price Today: Viatris Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Discipline and Rules-Based Execution in VTRS Response - Stock Traders Daily
Viatris in charts: Generic sales drop 16% in Q1; revenue from Developed Markets falls 13% - MSN
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
FDA Issues Nationwide Recall of ‘Extended Release’ Xanax for Anxiety - Healthline
Taking Xanax XR? FDA Recalls Batch Over Effectiveness Concerns - AOL.com
Viatris' Q1 2026 Earnings: What to Expect - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Viatris Inc. (VTRS) Stock Analysis: Navigating Challenges With A 7.10% Potential Upside - DirectorsTalk Interviews
Transdermal Skin Patches Market 2026- 2033 Overview: Share, - openPR.com
7.59%
0.09%
자본화:
|
볼륨(24시간):